Zumsteg ZS - Search Results

1

Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.

Spratt DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, Osborne JR, Pei X, Zelefsky MJ. Spratt DE, et al. Among authors: zumsteg zs. Eur Urol. 2017 Jan;71(1):37-43. doi: 10.1016/j.eururo.2016.07.043. Epub 2016 Aug 11. Eur Urol. 2017. PMID: 27523595 Free PMC article.

2

Malpractice Trends Involving Active Surveillance Across Cancers.

Chang S, Daskivich TJ, Vasquez M, Sacks WL, Zumsteg ZS, Ho AS. Chang S, et al. Among authors: zumsteg zs. Ann Surg. 2024 Apr 1;279(4):679-683. doi: 10.1097/SLA.0000000000006101. Epub 2023 Sep 25. Ann Surg. 2024. PMID: 37747179

3

Active Surveillance for Low-risk Papillary Thyroid Carcinoma-Reply.

Ho AS, Sacks WL, Zumsteg ZS. Ho AS, et al. Among authors: zumsteg zs. JAMA Oncol. 2023 May 1;9(5):722-723. doi: 10.1001/jamaoncol.2023.0006. JAMA Oncol. 2023. PMID: 36862392 No abstract available.

4

Inflammatory Tongue Conditions and Risk of Oral Tongue Cancer Among the US Elderly Individuals.

Tota JE, Engels EA, Lingen MW, Agrawal N, Kerr AR, Zumsteg ZS, Cheung LC, Katki HA, Abnet CC, Chaturvedi AK. Tota JE, et al. Among authors: zumsteg zs. J Clin Oncol. 2024 May 20;42(15):1745-1753. doi: 10.1200/JCO.23.00729. Epub 2023 Nov 30. J Clin Oncol. 2024. PMID: 38033283

5

Comparative impact of grade on mortality across salivary cancers: A novel, unifying staging system.

Ho AS, Luu M, Balzer BL, Aro K, Jang JK, Mita AC, Scher KS, Mallen-St Clair J, Vasquez M, Bastien AJ, Epstein JB, Lin DC, Chen MM, Zumsteg ZS. Ho AS, et al. Among authors: zumsteg zs. Head Neck. 2023 Aug;45(8):2028-2039. doi: 10.1002/hed.27429. Epub 2023 Jun 22. Head Neck. 2023. PMID: 37345665

6

Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?

Zumsteg ZS, Zelefsky MJ. Zumsteg ZS, et al. Lancet Oncol. 2012 Jun;13(6):e259-69. doi: 10.1016/S1470-2045(12)70084-0. Lancet Oncol. 2012. PMID: 22652234 Review.

7

Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.

Zumsteg ZS, Spratt DE, Pei X, Yamada Y, Kalikstein A, Kuk D, Zhang Z, Zelefsky MJ. Zumsteg ZS, et al. Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1012-7. doi: 10.1016/j.ijrobp.2012.07.2374. Epub 2012 Sep 14. Int J Radiat Oncol Biol Phys. 2013. PMID: 22981709

8

Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.

Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Spratt DE, et al. Among authors: zumsteg zs. Eur Urol. 2013 Apr;63(4):709-16. doi: 10.1016/j.eururo.2012.12.004. Epub 2012 Dec 14. Eur Urol. 2013. PMID: 23287698 Free PMC article.

9

A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.

Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, Zelefsky MJ. Zumsteg ZS, et al. Eur Urol. 2013 Dec;64(6):895-902. doi: 10.1016/j.eururo.2013.03.033. Epub 2013 Mar 23. Eur Urol. 2013. PMID: 23541457

10

Improved survival with surgery in prostate cancer patients without medical comorbidity: a self-fulfilling prophecy?

Zumsteg ZS, Zelefsky MJ. Zumsteg ZS, et al. Eur Urol. 2013 Sep;64(3):381-3. doi: 10.1016/j.eururo.2013.05.037. Epub 2013 May 28. Eur Urol. 2013. PMID: 23746719 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

125 results

Search Page

Filters